Randomized Phase III Trial of Cisplatin, Epirubicin, Leucovorin, 5-Fluorouracil (PELF) Combination versus 5-fluorouracil Alone as Adjuvant Chemotherapy in Curative Resected Stage III Gastric Cancer
Cancer Research and Treatment 2004³â 36±Ç 2È£ p.140 ~ p.145
ÀÌÀçÁø(Lee Jae-Jin) - °æÈñ´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
±è½Ã¿µ(Kim Si-Young) - °æÈñ´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
½ÅÀÓ½Ä(Shin Im-Sik) - °æÈñ´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
Á¶°æ»ï(Cho Kyung-Sam) - °æÈñ´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
ÁÖÈïÀç(Joo Hoong-Zae) - °æÈñ´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç
À±Ãæ(Yoon Choong) - °æÈñ´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç
(Kim Yoon-Wha) - °æÈñ´ëÇб³ ÀÇ°ú´ëÇÐ Çغκ´¸®Çб³½Ç
À±ÈÖÁß(Yoon Hwi-Joong) - °æÈñ´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
Abstract
Purpose: The combination of cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) administration, as adjuvant chemotherapy after curative resection for gastirc cancer, was compared with 5-fluorouracil (5-FU) administration alone. This paper reports the results of a prospective randomized comparison of the two regimens, PELF and 5-FU.
Methods: From August 1996 to July 1999, 54 patients were selected subsequent to being diagnosed with stage III cancer after a curative resection for gastric cancer. The patients were stratified according to stage IIIA/IIIB and subtotal/total gastrectomy, and then they were randomized into each treatment group, i.e. the PELF or 5-FU alone groups.
Results: 54 assessable patients were enrolled in this study: 28 received PELF and 26 received 5-FU alone. 12 patients relapsed in each group and the median follow-up duration was 42 months (range: 10~77 months). The overall survival rate and disease-free survival rate (DFS) were not significantly different between two groups, (5-year survival of PELF vs. 5-FU: 57% vs. 64%, 5-year DFS: 54% vs. 51%). The PELF combination was more toxic in terms of anemia, anorexia, nausea and diarrhea than the 5-FU.
Conclusions: This study showed that the PELF combination, as an adjuvant therapy for gastric cancer after a curative resection, was a less effective treatment, and it had more toxic effects than the 5-FU. (Cancer Research and Treatment 2004;36:140-145)
Å°¿öµå
Adjuvant chemotherapy, 5-Fluorouracil, Stomach neoplasm, Cisplatin, Epirubicin, Leucovorin, Phase III trial
KMID :
0939920040360020140
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
This study showed that the PELF combination, as an adjuvant therapy for gastric cancer after a curative resection, was a less effective treatment, and it had more toxic effects than the 5-FU.